ENCALS consensus statement on NurOwn
Background Given the interest around the use of stem cells in ALS,…
![Restez en [u]contact[/u]](/paper-plane.svg)
Apellis reports discontinuation of MERIDIAN study
Pharmaceutical company Apellis has announced the discontinuation of the open-label phase of…
Recording of virtual meeting – Adherence and retention in ALS clinical trials
On March 22, 2023, TRICALS organised its first virtual meeting: ‘Adherence and retention…
COURAGE-ALS trial discontinued due to disappointing results
The company Cytokinetics has announced early termination of the COURAGE-ALS study. An…
TRICALS consensus statement on Tofersen
OPINION: The consensus view of TRICALS neurologists is that Tofersen shows clear…
La Food and Drug Administration (FDA) approuve la commercialisation de l’AMX0035 (Amylyx) pour le marché américain
Au cours de la réunion de la commission consultative sur les médicaments…
Measuring treatment effects based on patient preference
To evaluate the effect of an investigational drug in ALS clinical trials,…
TRICALS Enrols First Participants in Phase 3 MAGNET platform trial for ALS
TRICALS (the Treatment Research Initiative to Cure ALS), in collaboration with ALS…
USA: new law promises $100 million for ALS research
A new law has been passed in the United States to give…
Congratulations to our TRICALS colleagues as UK Government invests £50 million to find a cure for ALS
The UK government has recently announced that £50 million will be invested…